Want to see OSUR full AI Analyst Report?
OSUR Stock Chart & Stats
$2.38
-$0.09(-2.38%)
At close: 4:00 PM EST
$2.38
-$0.09(-2.38%)
Day’s Range― - ―
52-Week Range$2.08 - $4.58
Previous CloseN/A
Volume226.53K
Average Volume (3M)771.42K
Market Cap
$299.49M
Enterprise Value$171.25M
Total Cash (Recent Filing)$176.96M
Total Debt (Recent Filing)$40.47M
Price to Earnings (P/E)―
Beta0.78
Next Earnings
Aug 11, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.04
Shares Outstanding68,848,560
10 Day Avg. Volume735,713
30 Day Avg. Volume771,421
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.52
Price to Sales (P/S)1.55
P/FCF Ratio-3.34K
Enterprise Value/Market Cap0.57
Enterprise Value/Revenue1.52
Enterprise Value/Gross Profit3.69
Enterprise Value/Ebitda-2.69
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.85
Revenue Forecast (FY)$119.68M
Bulls Say, Bears Say
Bulls Say
FDA Clearance — Colli‑PeeFDA clearance establishes a durable commercial pathway for at‑home first‑void urine collection integrated with major lab platforms (Roche). This materially expands addressable markets for specimen collection, strengthens lab partnerships, and creates recurring kit demand as adoption of remote sampling grows.
Strong Balance Sheet & Zero DebtSubstantial cash and near‑zero leverage provide strategic runway to fund product launches, near‑shoring initiatives, and commercial scale efforts while absorbing current cash burn. This financial flexibility reduces refinancing risk and supports optionality for M&A or continued capital returns.
Manufacturing Insourcing Improved Gross MarginsIn‑sourcing and manufacturing efficiencies that raised gross margins are structural improvements: they lower unit costs and increase operating leverage. As volume recovers, higher gross margins should translate into faster operating‑profit recovery and resilience versus external supply disruptions.
Bears Say
Negative Operating Cash FlowSustained negative operating cash flow consumes cash reserves and limits reinvestment flexibility. If revenue ramps are delayed, the company may need to cut spend or seek financing, which could dilute shareholders or slow commercialization of strategic products slated to drive medium‑term recovery.
Deep Operating LossesVery large negative margins signal the business is not yet earning returns on capital deployed. Persistent losses erode equity returns and require sustained revenue and margin improvement to restore profitability; absent that, strategic options and investor support become constrained.
Execution & Timing Risk For Product RampsKey growth relies on FDA approvals, partner ramps, and near‑shoring commercialization. Uncertain timing and unspecified partner order sizes create execution risk: delays or lower initial volumes could extend margin dilution and cash burn, making projected breakeven and accretion outcomes harder to realize.
Orasure Technologies News
OSUR FAQ
What was Orasure Technologies’s price range in the past 12 months?
Orasure Technologies lowest stock price was $2.08 and its highest was $4.58 in the past 12 months.
What is Orasure Technologies’s market cap?
Orasure Technologies’s market cap is $299.49M.
When is Orasure Technologies’s upcoming earnings report date?
Orasure Technologies’s upcoming earnings report date is Aug 11, 2026 which is in 36 days.
How were Orasure Technologies’s earnings last quarter?
Orasure Technologies released its earnings results on May 06, 2026. The company reported -$0.32 earnings per share for the quarter, missing the consensus estimate of -$0.23 by -$0.09.
Is Orasure Technologies overvalued?
According to Wall Street analysts Orasure Technologies’s price is currently Overvalued.
Does Orasure Technologies pay dividends?
Orasure Technologies does not currently pay dividends.
What is Orasure Technologies’s EPS estimate?
Orasure Technologies’s EPS estimate is -0.27.
How many shares outstanding does Orasure Technologies have?
Orasure Technologies has 68,848,560 shares outstanding.
What happened to Orasure Technologies’s price movement after its last earnings report?
Orasure Technologies reported an EPS of -$0.32 in its last earnings report, missing expectations of -$0.23. Following the earnings report the stock price went up 4.333%.
Which hedge fund is a major shareholder of Orasure Technologies?
Currently, no hedge funds are holding shares in OSUR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Orasure Technologies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
OSUR Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 159.0 Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $224.8K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.53%
12-Months-Change
Fundamentals
Return on Equity
-21.50%
Trailing 12-Months
Asset Growth
-17.14%
Trailing 12-Months
Company Description
Orasure Technologies
OraSure Technologies, Inc. and its affiliates are a global leader in the development, production, and commercialization of advanced oral fluid diagnostic solutions and specialized specimen collection tools, serving markets across the United States, Europe, and other international regions. The company operates through two primary divisions: Diagnostics and Molecular Solutions. Its diverse Diagnostics portfolio features a range of crucial offerings, such as the InteliSwab rapid tests for COVID-19 (including professional and prescription versions). It also provides several OraQuick rapid tests, encompassing solutions for HIV (Rapid, In-Home, and Self-Test versions), Hepatitis C (HCV rapid antibody), and Ebola (rapid antigen). Further diagnostic tools include the OraSure oral fluid collection device, utilized for HIV-1 antibody screening and confirmation; the Intercept drug testing systems; various immunoassay tests and reagents; and the Q.E.D. saliva alcohol test. Within its Molecular Solutions segment, OraSure offers an array of genomic products, notably under the Oragene and ORAcollect brand names, alongside specialized microbiome collection solutions and comprehensive GenoFIND genomics laboratory services. The company also supplies collection devices like ORAcollect, RNA, OMNIgene, and RAL, specifically designed for COVID-19 molecular testing. Another key offering is the Colli-Pee device, engineered for the precise volumetric collection of first-void urine. Furthermore, OraSure produces and distributes advanced kits for the collection, stabilization, transportation, and storage of genetic material samples, critical for molecular testing in diverse fields such as academic research, commercial applications (including ancestry, disease risk management, lifestyle analysis), and animal testing. Complementing these, it also provides various other diagnostic tools, including immunoassays and in vitro diagnostic tests. OraSure's sophisticated products and services are distributed to a wide array of clients, including clinical laboratories, hospitals, clinics, various community and public health organizations, wholesale distributors, governmental bodies, medical practices, and a broad spectrum of commercial and industrial entities. Established in 2000, OraSure Technologies, Inc. maintains its corporate headquarters in Bethlehem, Pennsylvania.
OSUR Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a balanced picture: positive execution on cost and manufacturing initiatives led to gross margin expansion and sequential diagnostics growth, a strong cash position and ongoing buybacks support financial flexibility, and two FDA-submitted products plus near-shoring progress are meaningful near- to mid-term growth catalysts. Offsetting these positives are substantial operating losses, negative operating cash flow, elevated near-term operating expenses (including nonrecurring charges), muted demand in some Sample Management end markets due to slow NIH funding, and execution/timing risks associated with product ramps and near-shoring monetization. Given the mix of encouraging operational progress and clear near-term financial and execution risks, the overall tone is balanced.View all OSUR earnings summariesTechnical Analysis
InfuSystem Holdings
―
Stereotaxis
―
Utah Medical Products
―
Microbot Medical
―
Sanara MedTech
―
Ownership Overview
5.63% Insiders
16.51% Mutual Funds
31.00% Other Institutional Investors
34.56% Public Companies and
Individual Investors









